Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

329 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients?
Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, Kaukonen KM, Koulenti D, Martin C, Montravers P, Rello J, Rhodes A, Starr T, Wallis SC, Lipman J; DALI Study. Roberts JA, et al. Among authors: paul sk. Clin Infect Dis. 2014 Apr;58(8):1072-83. doi: 10.1093/cid/ciu027. Epub 2014 Jan 14. Clin Infect Dis. 2014. PMID: 24429437
SaMpling Antibiotics in Renal Replacement Therapy (SMARRT): an observational pharmacokinetic study in critically ill patients.
Roberts JA, Choi GY, Joynt GM, Paul SK, Deans R, Peake S, Cole L, Stephens D, Bellomo R, Turnidge J, Wallis SC, Roberts MS, Roberts DM, Lassig-Smith M, Starr T, Lipman J. Roberts JA, et al. Among authors: paul sk. BMC Infect Dis. 2016 Mar 1;16:103. doi: 10.1186/s12879-016-1421-6. BMC Infect Dis. 2016. PMID: 26932762 Free PMC article.
The Effect of Renal Replacement Therapy and Antibiotic Dose on Antibiotic Concentrations in Critically Ill Patients: Data From the Multinational Sampling Antibiotics in Renal Replacement Therapy Study.
Roberts JA, Joynt GM, Lee A, Choi G, Bellomo R, Kanji S, Mudaliar MY, Peake SL, Stephens D, Taccone FS, Ulldemolins M, Valkonen MM, Agbeve J, Baptista JP, Bekos V, Boidin C, Brinkmann A, Buizen L, Castro P, Cole CL, Creteur J, De Waele JJ, Deans R, Eastwood GM, Escobar L, Gomersall C, Gresham R, Jamal JA, Kluge S, König C, Koulouras VP, Lassig-Smith M, Laterre PF, Lei K, Leung P, Lefrant JY, Llauradó-Serra M, Martin-Loeches I, Mat Nor MB, Ostermann M, Parker SL, Rello J, Roberts DM, Roberts MS, Richards B, Rodríguez A, Roehr AC, Roger C, Seoane L, Sinnollareddy M, Sousa E, Soy D, Spring A, Starr T, Thomas J, Turnidge J, Wallis SC, Williams T, Wittebole X, Zikou XT, Paul SK, Lipman J; SMARRT Study Collaborators and the ANZICS Clinical Trials Group. Roberts JA, et al. Among authors: paul sk. Clin Infect Dis. 2021 Apr 26;72(8):1369-1378. doi: 10.1093/cid/ciaa224. Clin Infect Dis. 2021. PMID: 32150603
Reply to Rhodes et al.
Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, Kaukonen KM, Koulenti D, Martin C, Montravers P, Rello J, Rhodes A, Starr T, Wallis SC, Lipman J. Roberts JA, et al. Among authors: paul sk. Clin Infect Dis. 2014 Sep 15;59(6):907-8. doi: 10.1093/cid/ciu403. Epub 2014 May 27. Clin Infect Dis. 2014. PMID: 24867785 No abstract available.
A Multicenter Randomized Trial of Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis.
Dulhunty JM, Roberts JA, Davis JS, Webb SA, Bellomo R, Gomersall C, Shirwadkar C, Eastwood GM, Myburgh J, Paterson DL, Starr T, Paul SK, Lipman J; BLING II Investigators for the ANZICS Clinical Trials Group *. Dulhunty JM, et al. Among authors: paul sk. Am J Respir Crit Care Med. 2015 Dec 1;192(11):1298-305. doi: 10.1164/rccm.201505-0857OC. Am J Respir Crit Care Med. 2015. PMID: 26200166 Clinical Trial.
Association between augmented renal clearance and clinical outcomes in patients receiving β-lactam antibiotic therapy by continuous or intermittent infusion: a nested cohort study of the BLING-II randomised, placebo-controlled, clinical trial.
Udy AA, Dulhunty JM, Roberts JA, Davis JS, Webb SAR, Bellomo R, Gomersall C, Shirwadkar C, Eastwood GM, Myburgh J, Paterson DL, Starr T, Paul SK, Lipman J; BLING-II Investigators; ANZICS Clinical Trials Group. Udy AA, et al. Among authors: paul sk. Int J Antimicrob Agents. 2017 May;49(5):624-630. doi: 10.1016/j.ijantimicag.2016.12.022. Epub 2017 Mar 9. Int J Antimicrob Agents. 2017. PMID: 28286115 Clinical Trial.
A protocol for a multicentre randomised controlled trial of continuous beta-lactam infusion compared with intermittent beta-lactam dosing in critically ill patients with severe sepsis: the BLING II study.
Dulhunty JM, Roberts JA, Davis JS, Webb SA, Bellomo R, Gomersall C, Shirwadkar C, Eastwood GM, Myburgh J, Paterson DL, Starr T, Udy AA, Paul SK, Lipman J; Australian and New Zealand Intensive Care Society Clinical Trials Group; Australasian Society for Infectious Diseases Clinical Research Network. Dulhunty JM, et al. Among authors: paul sk. Crit Care Resusc. 2013 Sep;15(3):179-85. Crit Care Resusc. 2013. PMID: 23944203 Clinical Trial.
Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial.
Harris PN, Peleg AY, Iredell J, Ingram PR, Miyakis S, Stewardson AJ, Rogers BA, McBryde ES, Roberts JA, Lipman J, Athan E, Paul SK, Baker P, Harris-Brown T, Paterson DL. Harris PN, et al. Among authors: paul sk. Trials. 2015 Jan 27;16:24. doi: 10.1186/s13063-014-0541-9. Trials. 2015. PMID: 25623485 Free PMC article. Clinical Trial.
329 results